Will NNRTIs be driving forward again ?

Calmy, Alexandra; Tarr, Philip E

doi:10.1016/S2352-3018(18)30037-7

Scientific article

Comment

English

Will NNRTIs be driving forward again ?

ContributorsCalmy, Alexandra

; Tarr, Philip E

Published inThe lancet. HIV, vol. 5, no. 5, p. e200-e201

Publication date2018-05

First online date2018-03-25

Abstract

Comment on : Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. PMID: 29592840.

Keywords

Anti-HIV Agents
HIV Infections
Humans
Reverse Transcriptase Inhibitors

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

VIH/SIDA (930)

Citation (ISO format)

CALMY, Alexandra, TARR, Philip E. Will NNRTIs be driving forward again ? In: The lancet. HIV, 2018, vol. 5, n° 5, p. e200–e201. doi: 10.1016/S2352-3018(18)30037-7

Article (Published version)

Identifiers

PID : unige:176279
DOI : 10.1016/S2352-3018(18)30037-7
PMID : 29592841

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S2352301818300377

Journal ISSN2352-3018

61views

0downloads

Creation07/02/2023 08:49:40

First validation10/04/2024 08:59:33

Update10/04/2024 08:59:33

Status update10/04/2024 08:59:33

Last indexation01/11/2024 09:11:32

Archive ouverte UNIGE

Will NNRTIs be driving forward again ?

Technical informations